Related Experiment Video

Updated: Apr 4, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.2K

Olaparib

S C Goulooze1, A F Cohen1,2, R Rissmann1,2

  • 1Centre for Human Drug Research, Leiden, the Netherlands.

British Journal of Clinical Pharmacology
|September 8, 2015
PubMed

Insights

Olaparib treats BRCA-associated ovarian cancer by inhibiting poly(ADP-ribose) polymerase. This blocks DNA repair, causing synthetic lethality in cancer cells with homologous recombination defects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Olaparib is a targeted therapy for specific cancers.
  • BRCA-associated cancers have impaired DNA repair mechanisms.
  • Platinum-sensitive ovarian cancer is a key indication.

Purpose of the Study:

  • To explain the mechanism of action of Olaparib.
  • To highlight its efficacy in BRCA-associated cancers.
  • To detail the concept of synthetic lethality in cancer treatment.

Main Methods:

  • Inhibition of poly(ADP-ribose) polymerase (PARP) by Olaparib.
  • Exploitation of homologous recombination pathway defects.
  • Induction of synthetic lethality in cancer cells.

Main Results:

  • Olaparib effectively blocks single-strand DNA break repair.
  • This leads to accumulation of DNA damage in cancer cells.
  • Synthetic lethality is achieved in BRCA-mutated cancer cells.

Conclusions:

  • Olaparib is a potent PARP inhibitor.
  • Its mechanism relies on synthetic lethality in BRCA-deficient cancers.
  • Olaparib offers a targeted treatment strategy for ovarian cancer.

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

Related Concept Videos

Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.6K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.3K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
4.7K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

2.6K
Base-pairing and DNA Repair02:27

Base-pairing and DNA Repair

94.4K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

13.9K